Xenon Pharmaceuticals Provides Update on Partnered Program with Neurocrine Biosciences
2023年11月10日 - 6:03AM
Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused
biopharmaceutical company, announced that its partner, Neurocrine
Biosciences, Inc., reported today that the Phase 2 clinical trial
evaluating NBI-921352 in adult patients with focal onset seizures
(FOS) failed to demonstrate meaningful reduction in seizure
frequency. Neurocrine Biosciences guided that no further
development with NBI-921352 in FOS is planned at this time.
Mr. Ian Mortimer, Xenon’s President and Chief
Executive Officer, stated, “Although we are disappointed with the
outcome of this clinical trial in focal onset seizures, we are
grateful to the study participants and investigators, as well as
our partner Neurocrine for running this proof-of-concept study. We
intend to work closely with Neurocrine to review the data in depth
to understand any potential implications for the second ongoing
study with NBI-921352 in SCN8A-developmental epileptic
encephalopathy. Neurocrine also continues to advance a pre-clinical
dual selective Nav1.2/1.6 inhibitor as part of our
collaboration.”
About Xenon Pharmaceuticals
Inc.
Xenon Pharmaceuticals (NASDAQ:XENE) is a
clinical stage biopharmaceutical company committed to developing
innovative therapeutics to improve the lives of patients with
neurological disorders. We are advancing a novel product pipeline
of neurology therapies to address areas of high unmet medical need,
with a focus on epilepsy. For more information, please visit
www.xenon-pharma.com.
Safe Harbor Statement
This press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended, and the Private Securities Litigation Reform
Act of 1995 and Canadian securities laws. These forward-looking
statements are not based on historical fact and include statements
regarding the timing of and potential results from clinical trials;
and the potential efficacy, safety profile, future development
plans, addressable market, regulatory success and commercial
potential of collaborators’ product candidates. These
forward-looking statements are based on current assumptions that
involve risks, uncertainties and other factors that may cause the
actual results, events, or developments to be materially different
from those expressed or implied by such forward-looking statements.
These risks and uncertainties, many of which are beyond our
control, include, but are not limited to: clinical trials may not
demonstrate safety and efficacy of any of our or our collaborators’
product candidates; promising results from pre-clinical development
activities or early clinical trial results may not be replicated in
later clinical trials; our ongoing discovery and pre-clinical
efforts may not yield additional product candidates; any of our or
our collaborators’ product candidates may fail in development, may
not receive required regulatory approvals, or may be delayed to a
point where they are not commercially viable; we may not achieve
additional milestones in our proprietary or partnered programs;
regulatory agencies may impose additional requirements or delay the
initiation of clinical trials; the impact of competition; the
impact of expanded product development and clinical activities on
operating expenses; the impact of new or changing laws and
regulations; the impact of pandemics, epidemics and other public
health crises on our research and clinical development plans and
timelines and results of operations, including impact on our
clinical trial sites, collaborators, regulatory agencies and
related review times, and contractors who act for or on our behalf;
the impact of unstable economic conditions in the general domestic
and global economic markets; adverse conditions from geopolitical
events; as well as the other risks identified in our filings with
the Securities and Exchange Commission and the securities
commissions in British Columbia, Alberta, and Ontario. These
forward-looking statements speak only as of the date hereof and we
assume no obligation to update these forward-looking statements,
and readers are cautioned not to place undue reliance on such
forward-looking statements.
“Xenon” and the Xenon logo are registered
trademarks or trademarks of Xenon Pharmaceuticals Inc. in various
jurisdictions. All other trademarks belong to their respective
owner.
Investor/Media Contact:Jodi RegtsXenon
Pharmaceuticals Inc.Phone: 604.484.3353Email:
investors@xenon-pharma.com
Xenon Pharmaceuticals (NASDAQ:XENE)
過去 株価チャート
から 5 2024 まで 6 2024
Xenon Pharmaceuticals (NASDAQ:XENE)
過去 株価チャート
から 6 2023 まで 6 2024